Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Antibodies are widely considered to be a frequent primary and often mechanistic correlate of protection of approved vaccines; thus evaluating the antibody response is of critical importance in attempting to understand and predict the efficacy of novel vaccine candidates. Historically, antibody responses have been analyzed by determining the titer of the humoral response using measurements such as an ELISA, neutralization, or agglutination assays. In the simplest case, sufficiently high titers of antibody against vaccine antigen(s) are sufficient to predict protection. However, antibody titer provides only a partial measure of antibody function, which is dependent on both the variable region (Fv) to bind the antigen target, and the constant region (Fc) to elicit an effector response from the innate arm of the immune system. In the case of some diseases, such as HIV, for which an effective vaccine has proven elusive, antibody effector function has been shown to be an important driver of monoclonal antibody therapy outcomes, of viral control in infected patients, and of vaccine-mediated protection in preclinical and clinical studies. We sought to establish a platform for the evaluation of the Fc domain characteristics of antigen-specific antibodies present in polyclonal samples in order to better develop insights into Fc receptor-mediated antibody effector activity, more fully understand how antibody responses may differ in association with disease progression and between subject groups, and differentiate protective from non-protective responses. To this end we have developed a high throughput biophysical platform capable of simultaneously evaluating many dimensions of the antibody effector response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“…of such effector functions has long been recognized in the fi eld of therapeutic monoclonal antibodies (Cartron et al., 2002; Liu et al., 2014; Gennari et al., 2004; Niwa et al., 2005; Pincetic et al., 2014; Taylor and Lindorfer, 2008; Clynes et al., 2000; Musolino et al., 2008; Jefferis, 2009a).”
BackgroundCorrelates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745 · cited 2×
“neutralize infectious particles (to prevent infection of target cells), or to agglutinate target cells (to facilitate their clearance), to fix complement, to induce opsonophagocytosis, or exhibit bactericidal activity have also been primary correlates of protection (Plotkin, 2010).”
Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., Uchida, K., Anazawa, H., Satoh, M., Yamasaki, M., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210665200 · Cited by 1,413 · cited 1×
“The PCA analysis function prcomp was used for generating lead PCs.”
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981 · cited 1×
“…of such effector functions has long been recognized in the fi eld of therapeutic monoclonal antibodies (Cartron et al., 2002; Liu et al., 2014; Gennari et al., 2004; Niwa et al., 2005; Pincetic et al., 2014; Taylor and Lindorfer, 2008; Clynes et al., 2000; Musolino et al., 2008; Jefferis, 2009a).”
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829 · cited 3×
“…of such effector functions has long been recognized in the fi eld of therapeutic monoclonal antibodies (Cartron et al., 2002; Liu et al., 2014; Gennari et al., 2004; Niwa et al., 2005; Pincetic et al., 2014; Taylor and Lindorfer, 2008; Clynes et al., 2000; Musolino et al., 2008; Jefferis, 2009a).”
DiLillo, D. J., Tan, G. S., Palese, P., & Ravetch, J. V. (2014) · Nature Medicine · doi:10.1038/nm.3443 · Cited by 749 · cited 1×
“The importance of effector function in control of and protection from disease has been repeatedly demonstrated across many different systems (DiLillo et al., 2014; Bournazos et al., 2014a; Benhnia et al., 2013; Bournazos et al., 2014b; Kapur et al., 2014).”
BackgroundHigh-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples
Brown, E. P., Licht, A. F., Dugast, A.-S., Choi, I., Bailey-Kellogg, C., Alter, G., & Ackerman, M. E. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.09.007 · Cited by 231
Self-citationNiwa, R., Sakurada, M., Kobayashi, Y., Uehara, A., Matsushima, K., Ueda, R., Nakamura, K., & Shitara, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2263 · Cited by 187 · cited 1×
“…of such effector functions has long been recognized in the fi eld of therapeutic monoclonal antibodies (Cartron et al., 2002; Liu et al., 2014; Gennari et al., 2004; Niwa et al., 2005; Pincetic et al., 2014; Taylor and Lindorfer, 2008; Clynes et al., 2000; Musolino et al., 2008; Jefferis, 2009a).”
Barnett, S. W., Burke, B., Sun, Y., Kan, E., Legg, H., Lian, Y., Bost, K., Zhou, F., Goodsell, A., zur Megede, J., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02533-09 · Cited by 82 · cited 1×
“…that protect by similar mechanisms in vaccine settings through the use of different adjuvant preparations (Moody, 2014; Moody et al., 2014; Barnett et al., 2010), delivery methods (Barouch et al., 2015), or routes of administration (Brekke et al., 2014; Singh et al., 2014; Maeto et al.,…”
Cited by
Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques
McMahan, K., Yu, J., Mercado, N. B., Loos, C., Tostanoski, L. H., Chandrashekar, A., Liu, J., Peter, L., Atyeo, C., Zhu, A., et al. (2021) · Nature · doi:10.1038/s41586-020-03041-6 · Cited by 1,068
Self-citationSingle-Shot Ad26 Vaccine Protects Against SARS-CoV-2 in Rhesus Macaques
Mercado, N. B., Zahn, R., Wegmann, F., Loos, C., Chandrashekar, A., Yu, J., Liu, J., Peter, L., McMahan, K., Tostanoski, L. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2607-z · Cited by 789
Self-citationErbelding, E. J., Post, D. J., Stemmy, E. J., Roberts, P. C., Augustine, A. D., Ferguson, S., Paules, C. I., Graham, B. S., & Fauci, A. S. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy103 · Cited by 438
Distinct Early Serological Signatures Track with SARS-CoV-2 Survival
Atyeo, C., Fischinger, S., Zohar, T., Slein, M. D., Burke, J., Loos, C., McCulloch, D. J., Newman, K. L., Wolf, C., Yu, J., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.020 · Cited by 349
Self-citationSuscovich, T. J., Fallon, J. K., Das, J., Demas, A. R., Crain, J., Linde, C. H., Michell, A., Natarajan, H., Arevalo, C., Broge, T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb4757 · Cited by 142
Self-citation
Metadata
- Authors
- Brown, E. P., Dowell, K. G., Boesch, A. W., Normandin, E., Mahan, A. E., Chu, T., Barouch, D. H., Bailey-Kellogg, C., Alter, G., & Ackerman, M. E.
- Venue
- Journal of Immunological Methods
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 443
- Pages
- 33-44
- ISSN
- 0022-1759 (ISSN-L)
- OpenAlex
- W2585172252
- Cited by
- 195
- References
- 9
- FWCI
- 7.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. https://app.cochat.ai/papers/10.1016/j.jim.2017.01.010
- The paper
- Brown, E. P., Dowell, K. G., Boesch, A. W., Normandin, E., Mahan, A. E., Chu, T., Barouch, D. H., Bailey-Kellogg, C., Alter, G., & Ackerman, M. E. (2017). Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles. Journal of Immunological Methods. https://doi.org/10.1016/j.jim.2017.01.010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.